Switzerland | Page 11 of 13

Multiple Myeloma :: Long-term therapy in the fight against multiple myeloma cancer

There is no known cure for multiple myeloma, so its diagnosis means high-dose chemotherapy followed by repeated treatments with each relapse of the cancer ? a watch and wait approach. A new approach of providing patients with continuous therapy to keep the cancer at bay was explored by a team of international researchers from France, Switzerland, and Belgium; their findings will be published in the November 15, 2006, issue of Blood, the official journal of the American Society of Hematology.

Diet :: Lipopan Xtra – new alternative to chemical additives in bread making

Novozymes launches another cost-effective new baking enzyme to replace chemical emulsifiers and reduce costs in bread-making.

Alzheimer’s Disease :: Therapeutic approaches to Alzheimer’s Disease

Alzheimer’s disease is an age-related progressive neurodegenerative disorder with an enormous unmet medical need. It is the most common form of dementia affecting 5% of adults over 65 years. In view of our ageing society the number of patients, as well as the economical and social impact, is expected to grow dramatically in the future. Currently available medications appear to be able to produce moderate symptomatic benefits but not to stop disease progression.

Depression :: Persistent adolescent depression impacts on adult functioning

Adolescents who experience persistent depression appear to be at greater risk of abnormal psychosocial and mental functioning in young adulthood than those who have episodic depression, research reveals.

Tuberculosis :: A large, untapped global market exists for improved TB tests

A significant and largely untapped global market exists for more effective and affordable tests to diagnose tuberculosis in low and middle income countries, where most TB cases today occur.

Hepatitis :: Tyzeka, Sebivo or telbivudine for patients with chronic hepatitis B – Novartis

Novartis announced the US regulatory approval of Tyzeka(TM) (telbivudine) as a new once-a-day oral treatment for patients with chronic hepatitis B, a disease estimated to affect about 1.25 million people in the US but more than 350 million globally and considered the tenth leading cause of death.

Health :: Glivec, imatinib approved for five rare life threatening disorders

In another important milestone, Glivec? (imatinib) has received US regulatory approval to help patients with five distinct and potentially life-threatening disorders, representing the first time that a regulatory authority has ever simultaneously approved one targeted medicine for so many disorders. With today’s decision, and in only five years, Glivec has now been approved in the US for seven diseases, including two solid tumors and five blood disorders with molecular targets known to be inhibited by the drug.

Influenza :: Novartis cell culture-derived influenza vaccine well tolerated and efficacious

Novartis (NYSE: NVS) announced today results of pivotal Phase III clinical trial data for its innovative cell culture-derived influenza vaccine demonstrating that it is highly capable of producing an immune response (“immunogenic”), one at least as strong as the traditional egg-derived influenza vaccine Aggripal? for each of the three influenza strains studied.

Diabetes :: Merck KGaA & Glenmark Pharmaceuticals Collaboration on DPPIV Inhibitor for Type 2 Diabetes

Merck KGaA and Glenmark Pharmaceuticals S.A (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL), have entered into an agreement for Glenmark?s DPPIV inhibitor GRC 8200, a treatment for type 2 diabetes in Phase II of clinical development. The transaction is expected to close this year upon approval of the exclusive license to GRC 8200 by the U.S. anti-trust agencies under the HSR Act.

Hepatitis :: Roche and InterMune’s ITMN-191 HCV protease inhibitor for hepatitis c

Roche and InterMune Inc. announced that the companies have entered into an exclusive worldwide collaboration agreement to develop and commercialize products from InterMune?s Hepatitis C (HCV) protease inhibitor program. The agreement includes InterMune?s lead candidate compound ITMN-191, expected to enter clinical trials before the end of the year. The companies will also collaborate on a research program to identify, develop and commercialize novel second-generation HCV protease inhibitors.